Evidence map›Paper›PMID 30726727›Full record

ArticleCell reports2019

HIV-1 and SIV Infection Are Associated with Early Loss of Lung Interstitial CD4+ T Cells and Dissemination of Pulmonary Tuberculosis.

Björn Corleis, Allison N Bucsan, Maud Deruaz, Vladimir D Vrbanac, Antonella C Lisanti-Park, Samantha J Gates, Alice H Linder, Jeffrey M Paer, Gregory S Olson, Brittany A Bowman and 7 more

Open access · goldAbstract read
In one paragraph

Article in Cell reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.

  1. The Hitchhiker Guide to CD4Frontiers in immunology · 2021
    Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Observational
  12. Review
  13. A world without tuberculosis: moving from imagination to reality.The Journal of clinical investigation · 2022
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 1 country.

Björn CorleisRagon Institute of MGH, MIT, and Harvard, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: bcorleis@mgh.harvard.edu.
Allison N BucsanTulane National Primate Research Center, Covington, LA, USA; Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, LA, USA.
Maud DeruazRagon Institute of MGH, MIT, and Harvard, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA.
Vladimir D VrbanacRagon Institute of MGH, MIT, and Harvard, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA.
Antonella C Lisanti-ParkRagon Institute of MGH, MIT, and Harvard, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Samantha J GatesRagon Institute of MGH, MIT, and Harvard, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Alice H LinderRagon Institute of MGH, MIT, and Harvard, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Jeffrey M PaerRagon Institute of MGH, MIT, and Harvard, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Gregory S OlsonRagon Institute of MGH, MIT, and Harvard, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Brittany A BowmanRagon Institute of MGH, MIT, and Harvard, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Abigail E SchiffRagon Institute of MGH, MIT, and Harvard, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Benjamin D MedoffCenter for Immunology and Inflammatory Diseases, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA; Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA, USA.
Andrew M TagerRagon Institute of MGH, MIT, and Harvard, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA; Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA, USA.
Andrew D LusterCenter for Immunology and Inflammatory Diseases, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA.
Shabaana A KhaderDepartment of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA.
Deepak KaushalTulane National Primate Research Center, Covington, LA, USA; Southwest National Primate Research Center, San Antonio, TX, USA.
Douglas S KwonRagon Institute of MGH, MIT, and Harvard, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.
Harvard University · USRagon Institute of MGH, MIT and Harvard · USTulane University · USMassachusetts General Hospital · USWashington University in St. Louis · US

Funding

The Southwest National Primate Research Center Supplement- Infrastructure improvements of ABSL2 holding areasP51OD011133 · OD · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI Larry S. Schlesinger · 2012 to 2026
$129.7M
The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI RAJESH T GANDHI · 2004 to 2026
$94.4M
Medical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0M
Pilot & Feasibility ProgramP30DK043351 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI RAYMOND T CHUNG · 1991 to 2026
$35.3M
ROLE OF INDUCIBLE BRONCHUS ASSOCIATED LYMPHOID TISSUE IN LATENT TUBERCULOSISR01AI111914 · NIAID · WASHINGTON UNIVERSITY · PI KAUSHAL, DEEPAK, KHADER, SHABAANA A. · 2015 to 2025
$11.1M
P3: Chemokine-Mediated T Cell Trafficking in HIV Transmission and Immune ResponseP01AI112521 · NIAID · HARVARD MEDICAL SCHOOL · PI LUSTER, ANDREW · 2014 to 2018
$9.8M
Lung-Resident Memory Th2 cells in Asthma - New Therapeutic TargetsR01AI040618 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LUSTER, ANDREW D · 1997 to 2022
$5.6M
Chemokines and Th2 Cell Trafficking in AsthmaR37AI040618 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LUSTER, ANDREW D · 2008 to 2017
$4.0M
Perturbation of antigen-specific T cell responses in latent TB/SIV co-infectionR01AI111943 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI KAUSHAL, DEEPAK, RENGARAJAN, JYOTHI · 2015 to 2019
$3.9M
Impact of concurrent HIV and latent TB therapies on Mtb-specific immune function-Diversity SupplementR01AI123047 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI KAUSHAL, DEEPAK, RENGARAJAN, JYOTHI · 2017 to 2020
$3.9M
HIV and COPD:Immune mediated mechanismsU01HL121827 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI KWON, DOUGLAS, MEDOFF, BENJAMIN DAVID · 2013 to 2017
$3.2M
Genetic Requirements for the survival of Tubercle Bacilli in Nonhuman PrimatesR01AI089323 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI KAUSHAL, DEEPAK · 2010 to 2014
$3.2M
NCRR NIH HHS R21 RR026006NHLBI NIH HHS F30 HL134566NHLBI NIH HHS R01 HL106790NHLBI NIH HHS U01 HL121827NIAID NIH HHS P01 AI112521NIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI040618NIAID NIH HHS R01 AI089323NIAID NIH HHS R01 AI111914NIAID NIH HHS R01 AI111943NIAID NIH HHS R01 AI123047NIAID NIH HHS R01 AI123780NIAID NIH HHS R37 AI040618NIDDK NIH HHS P30 DK043351NIGMS NIH HHS T32 GM007753NIH HHS P51 OD011133
6 · The paper itself

Abstract

Lung interstitial CD4+ T cells are critical for protection against pulmonary infections, but the fate of this population during HIV-1 infection is not well described. We studied CD4+ T cells in the setting of HIV-1 infection in human lung tissue, humanized mice, and a Mycobacterium tuberculosis (Mtb)/simian immunodeficiency virus (SIV) nonhuman primate co-infection model. Infection with a CCR5-tropic strain of HIV-1 or SIV results in severe and rapid loss of lung interstitial CD4+ T cells but not blood or lung alveolar CD4+ T cells. This is accompanied by high HIV-1 production in these cells in vitro and in vivo. Importantly, during early SIV infection, loss of lung interstitial CD4+ T cells is associated with increased dissemination of pulmonary Mtb infection. We show that lung interstitial CD4+ T cells serve as an efficient target for HIV-1 and SIV infection that leads to their early depletion and an increased risk of disseminated tuberculosis.

Indexed as

AnimalsCD4-Positive T-LymphocytesCoinfectionFemaleHEK293 CellsHIV-1HIV InfectionsHumansLungMacaca mulattaMiceMycobacterium tuberculosisSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusTuberculosis, PulmonaryBALCD4+ T cellscell deathHIV-1HIV/TB co-infectionlungtuberculosis

Identifiers

PMID30726727
PMCPMC6417097
OpenAlexW2914779888

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.